My group aims to develop new radioisotope-labelled compounds for the imaging of tumour biology.
Bart is CRUK Junior Group Leader based at the Oxford Institute for Radiation Oncology and has headed the Radiopharmaceuticals and Molecular Imaging group since early 2013. He also holds an appointment at the University Medical Center Groningen's Department of Nuclear Medicine and Molecular Imaging.
Bart trained in analytical chemistry and radiochemistry at the Universities of Hasselt and Ghent, Belgium. He obtained his PhD in radiopharmaceutical sciences from the University of Ghent and spent several years at the University of Toronto as a post-doctoral fellow before joining the University of Oxford in 2007 as a postdoctoral researcher in Professor Kate Vallis’ group.
Group Alumni & Next Destinations
James Knight, Postdoctoral Researcher - Newcastle University
Samantha Hopkins, Postdoctoral Researcher - Randolph-Macon College, Ashland, VA, USA
Emerging chelators for nuclear imaging.
CORNELISSEN B. and SNEDDON D., (2021), Current Opinion in Chemical Biology
A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear Epitopes
Veal M. et al, (2021), Journal of Nuclear Medicine
Chan TG. et al, (2020), J Nucl Med, 61, 1544 - 1552
PARP Inhibitors in Cancer Diagnosis and Therapy
CHAN C. et al, (2020), Clinical Cancer Research
Exploring the limits of intranuclear PET/SPECT imaging with IgG-TAT: how low can you go?
Veal M. et al, (2020), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47, S78 - S78